Please assess the completion status of the following clinical trial:

Trial Title: Phase I Trial HIPEC With Nal-irinotecan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with pseudomyxoma peritonei or peritoneal carcinomatosis of digestive origin or primary peritoneum: appendiceal mucinous tumor or adenocarcinoma (including goblet cell cancer and signet ring cell cancer), colorectal cancer, gastric cancer, primary peritoneal adenocarcinoma, and mesothelioma; regardless of the number of prior treatment lines. Diagnosis of peritoneal metastasis to be confirmed via either clinical or histopathology assessment.~2. Age ≥18 years~3. Eastern Cooperative Oncology Group performance status of 0 or 1~4. Patients must be candidates for grossly complete cytoreduction surgery with life expectancy greater than 3 months~5. Patients must have normal organ and marrow function as defined below:~   * absolute neutrophil count \>1,500/microliter (mcL) and white blood cells \> 4000/mm3~  * platelets \>75,000/microliters~  * total bilirubin \< 3x upper limit normal for institutional limits~  * aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) \<2.5x institutional upper limit of normal~  * creatinine within normal institutional limits~6. Documentation of resectable disease extent by radiographic peritoneal carcinomatosis index (PCI) score or preoperative diagnostic surgery/laparoscopy with preoperative measurements taken within 6 weeks of study entry.~7. Women of child-bearing potential and men must agree to use adequate contraception (barrier or hormonal plus barrier method of birth control; abstinence) prior to study entry and for the duration of study participation (at least first 6 months). Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.~8. Ability to understand and the willingness to sign a written informed consent document.~Exclusion Criteria:~1. Patients with peritoneal disease considered to be unresectable according to preoperative clinical criteria.~2. Patients who undergo debulking for palliation with persistence of gross residual disease (complete of cytoreduction score 3, CC=3) will be ineligible for the study.~3. Large burden visceral metastases or extra-abdominal metastases.~4. Patients who have had radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier. There is no limit on the number of prior lines of chemotherapy.~5. Patients may not be receiving any other investigational agents.~6. History of allergic reactions to nal-IRI or irinotecan.~7 Uncontrolled ongoing illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.~8 Pregnant or breast-feeding women are excluded from this study.~9 HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Cytoreductive surgery (CRS) followed by study treatment with nanoliposomal irinotecan administered intraperitoneally.

Based on this trial design, predict the completion outcome and termination type (if applicable).